美国胰臟癌治疗市场规模、份额、趋势分析报告：按类型、治疗方法、分销管道和细分市场预测，2025-2030 年

美国胰臟癌治疗市场的成长与趋势

根据Grand View Research, Inc.的最新报告，美国胰臟癌治疗市场预计到2030年将达到20.1亿美元，2025年至2030年期间的复合年增长率为12.02%。

这一市场的发展受到胰腺癌发病率上升、肿瘤学研究资金增加以及 FDA 对新型治疗方法的核准。发病率上升、人口老化、治疗技术的进步以及强大的医疗保健基础设施是影响市场的关键因素。

胰臟癌是最具侵袭性和致命性的癌症之一，其特征是存活率低。然而，标靶治疗、免疫疗法和手术的最新发展正在开创治疗这种疾病的新时代。胰臟癌的治疗方案包括手术、化疗、放射疗法以及标靶治疗和免疫疗法等新兴疗法。手术切除仍然是唯一的根治性方法，但由于诊断晚期，只有 10%-20% 的患者可以接受手术。化疗，特别是以Gemcitabine为基础的联合疗法（如 FOLFIRINOX）仍然是标准治疗方法。同时，针对 KRAS 和 BRCA1/2 等基因突变的标靶治疗以及查核点抑制剂等免疫疗法也越来越受欢迎。

美国胰臟癌治疗市场的一些知名公司包括罗氏、礼来公司、百时美施贵宝、阿斯特捷利康和安进公司。这些公司正在大力投资研发，并正在开发多种新疗法。儘管取得了进展，但市场仍面临一些挑战。延迟诊断限制了许多患者的治疗选择，而先进的治疗费用昂贵。此外，缺乏可靠的生物标记继续阻碍早期检测和个人化治疗的发展。

美国胰臟癌治疗市场未来可能会取得长足发展。精准医疗方法将透过识别可操作的突变实现更个人化的治疗。基于人工智慧的早期检测和治疗计画工具正变得越来越普及，而合作研究倡议正在加速药物开发和临床试验。官民合作关係在解决胰臟癌治疗中未满足的需求方面也发挥着重要作用。

美国胰臟癌治疗市场正在呈现出变革性成长的迹象。儘管挑战依然存在，最尖端科技与创新治疗的结合为改善患者治疗效果带来了希望。包括製药公司、研究人员和医疗保健提供者在内的相关人员正在共同努力，解决受这种毁灭性疾病影响的患者和家庭的关键需求。未来十年有望重塑胰臟癌治疗格局，并为更好地治疗这种疾病提供新的希望和机会。

美国胰臟癌治疗市场报告重点

• 根据类型，外分泌部分在 2024 年美国胰臟癌治疗市场中占据最大收入份额，为 43.25%。这项优势归功于外分泌型胰臟癌的发生率高，占胰臟癌的大多数，以及针对此类癌症的标靶治疗的进展。
• 根据治疗方法，化疗占据市场主导地位，占有 43.25% 的份额，预计在预测期内仍将保持领先地位。化疗，特别是广泛使用以Gemcitabine为基础的方案和 FOLFIRINOX，儘管存在抗药性和副作用等挑战，但仍有助于治疗胰腺癌。
• 从分销管道来看，医院药房预计将在 2024 年占据最大的销售份额，达到 46.01%，并继续引领市场。这是因为医院在管理复杂的治疗方法中发挥重要作用，而且因诊断和治疗胰臟癌而住院的患者数量也在增加。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章美国胰臟癌治疗市场变数、趋势与范围

• 母市场展望
• 补贴市场前景
• 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
• 胰臟癌治疗分析工具
  • 波特的分析
  • PESTEL 分析

第 4 章美国胰臟癌治疗市场：按类型估计和趋势分析

• 美国胰臟癌治疗市场：类型细分仪表板
• 美国胰臟癌治疗市场：类型变化分析，2024 年与 2030 年
• 外分泌
• 内分泌

第 5 章美国胰臟癌治疗市场：治疗方法的估计和趋势分析

• 美国胰臟癌治疗市场：治疗细分仪表板
• 美国胰臟癌治疗市场：2024 年和 2030 年治疗变化分析
• 化疗
• 放射治疗
• 其他的

第 6 章：美国胰臟癌治疗市场通路、估计与趋势分析

• 美国胰臟癌治疗市场：通路细分仪表板
• 美国胰臟癌治疗市场：2024 年和 2030 年分销管道变化分析
• 医院药房
• 零售药局
• 其他的

第七章 竞争格局

• 主要市场参与企业的近期趋势和影响分析
• 公司分类
• 公司热图分析
• 公司简介
  • Accuray Incorporated
  • AstraZeneca
  • Novartis AG
  • Pfizer Inc.
  • Genentech, Inc.（F. Hoffmann-La Roche Ltd）
  • Bristol-Myers Squibb Company
  • Ipsen Pharma
  • Eli Lilly and Company
  • Siemens Healthineers AG（Varian Medical Systems, Inc.）
  • Elekta AB

U.S. Pancreatic Cancer Treatment Market Growth & Trends:

The U.S. pancreatic cancer treatment market is anticipated to reach USD 2.01 billion by 2030 and is expected to grow at a CAGR of 12.02% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the rising prevalence of pancreatic cancer, increased funding for oncology research, and FDA approvals for novel therapies. Rising incidence rates, an aging population, therapeutic advances, and robust healthcare infrastructure are key factors influencing the market.

Pancreatic cancer is one of the most aggressive and lethal forms of cancer, characterized by poor survival rates. However, recent developments in targeted therapies, immunotherapies, and surgical procedures are shaping a new era for managing the disease.Treatment options for pancreatic cancer include surgery, chemotherapy, radiation therapy, and emerging therapies such as targeted therapy and immunotherapy. Surgical resection remains the only potential curative option but is viable for only 10-20% of patients due to late-stage diagnosis. Chemotherapy, particularly gemcitabine-based combinations like FOLFIRINOX, continues to be the standard treatment. Meanwhile, targeted therapies focusing on genetic mutations such as KRAS and BRCA1/2 and immunotherapy approaches like checkpoint inhibitors are gaining traction.

Prominent U.S. pancreatic cancer treatment market players include Roche, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca, and Amgen Inc. These companies are actively investing in research and development, with several novel therapies in the pipeline.Despite advancements, the market faces several challenges. Late diagnosis limits treatment options for many patients, while the high costs of advanced therapies can be prohibitive. Additionally, the lack of reliable biomarkers continues to hamper early detection and the development of personalized treatments.

Looking forward, the U.S. pancreatic cancer treatment market is poised for significant advancements. Efforts in precision medicine enable more personalized treatments by identifying actionable mutations. Artificial intelligence-based tools for early detection and treatment planning are gaining traction, while collaborative research initiatives are accelerating drug development and clinical trials. Public-private partnerships are also playing a crucial role in addressing unmet needs in pancreatic cancer treatment.

The U.S. pancreatic cancer treatment market is on the cusp of transformative growth. While challenges persist, the integration of cutting-edge technologies and innovative therapies offers hope for improved patient outcomes. Stakeholders, including pharmaceutical companies, researchers, and healthcare providers, are working collaboratively to address the critical needs of patients and families affected by this devastating disease. The next decade promises to reshape the landscape of pancreatic cancer treatment, offering new hope and opportunities for better management of this condition.

U.S. Pancreatic Cancer Treatment Market Report Highlights:

• On the basis of type, the exocrine segment held the largest revenue share of 43.25% of the U.S. pancreatic cancer treatment market in 2024. This dominance is attributed to the high prevalence of exocrine pancreatic cancer, which accounts for the majority of cases, and advancements in treatment modalities targeting this type.
• Based on treatment, the chemotherapy dominated the market with a share of 43.25% and is expected to maintain its lead during the forecast period. The widespread use of chemotherapy, particularly gemcitabine-based regimens and FOLFIRINOX, has been instrumental in managing pancreatic cancer, despite challenges such as resistance and side effects.
• Based on distribution channel, the hospital pharmacies accounted for the largest revenue share of 46.01% in 2024 and are expected to continue leading the market. This is due to the critical role hospitals play in administering complex treatment regimens, coupled with the increasing number of inpatient visits for pancreatic cancer diagnosis and treatment.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Pancreatic Cancer Treatment Market Variables, Trends, & Scope

• 3.1. Parent Market Outlook
• 3.2. Ancillary Market Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
    • 3.3.1.1. Rising Prevalence of Pancreatic Cancer
    • 3.3.1.2. Advancements in Modern Therapeutics
    • 3.3.1.3. Growing Investments in Pancreatic Cancer R&D
  • 3.3.2. Market Restraints Analysis
    • 3.3.2.1. High Cost of Advanced Therapies
    • 3.3.2.2. Stringent Regulatory and Reimbursement Challenges
• 3.4. Pancreatic Cancer Treatment Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. U.S. Pancreatic Cancer Treatment Market: By Type Estimates & Trend Analysis

• 4.1. U.S. Pancreatic Cancer Treatment Market: Type Segment Dashboard
• 4.2. U.S. Pancreatic Cancer Treatment Market: By Type Movement Analysis, 2024 & 2030 (USD Million)
• 4.3. Exocrine
  • 4.3.1. Exocrine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Endocrine
  • 4.4.1. Endocrine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Pancreatic Cancer Treatment Market: Treatment Estimates & Trend Analysis

• 5.1. U.S. Pancreatic Cancer Treatment Market: Treatment Segment Dashboard
• 5.2. U.S. Pancreatic Cancer Treatment Market: By Treatment Movement Analysis, 2024 & 2030 (USD Million)
• 5.3. Chemotherapy
  • 5.3.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Radiation Therapy
  • 5.4.1. Radiation Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Others
  • 5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Pancreatic Cancer Treatment Market: Distribution Channel Estimates & Trend Analysis

• 6.1. U.S. Pancreatic Cancer Treatment Market: Distribution Channel Segment Dashboard
• 6.2. U.S. Pancreatic Cancer Treatment Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
• 6.3. Hospital Pharmacies
  • 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Retail Pharmacies
  • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Others
  • 6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis by Key Market Participants
• 7.2. Company Categorization
• 7.3. Company Heat Map Analysis
• 7.4. Company Profiles
  • 7.4.1. Accuray Incorporated
    • 7.4.1.1. Participant's Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Product Benchmarking
    • 7.4.1.4. Recent Developments/ Strategic Initiatives
  • 7.4.2. AstraZeneca
    • 7.4.2.1. Participant's Overview
    • 7.4.2.2. Financial Performance
    • 7.4.2.3. Product Benchmarking
    • 7.4.2.4. Recent Developments/ Strategic Initiatives
  • 7.4.3. Novartis AG
    • 7.4.3.1. Participant's Overview
    • 7.4.3.2. Financial Performance
    • 7.4.3.3. Product Benchmarking
    • 7.4.3.4. Recent Developments/ Strategic Initiatives
  • 7.4.4. Pfizer Inc.
    • 7.4.4.1. Participant's Overview
    • 7.4.4.2. Financial Performance
    • 7.4.4.3. Product Benchmarking
    • 7.4.4.4. Recent Developments/ Strategic Initiatives
  • 7.4.5. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
    • 7.4.5.1. Participant's Overview
    • 7.4.5.2. Financial Performance
    • 7.4.5.3. Product Benchmarking
    • 7.4.5.4. Recent Developments/ Strategic Initiatives
  • 7.4.6. Bristol-Myers Squibb Company
    • 7.4.6.1. Participant's Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Product Benchmarking
    • 7.4.6.4. Recent Developments/ Strategic Initiatives
  • 7.4.7. Ipsen Pharma
    • 7.4.7.1. Participant's Overview
    • 7.4.7.2. Financial Performance
    • 7.4.7.3. Product Benchmarking
    • 7.4.7.4. Recent Developments/ Strategic Initiatives
  • 7.4.8. Eli Lilly and Company
    • 7.4.8.1. Participant's Overview
    • 7.4.8.2. Financial Performance
    • 7.4.8.3. Product Benchmarking
    • 7.4.8.4. Recent Developments/ Strategic Initiatives
  • 7.4.9. Siemens Healthineers AG (Varian Medical Systems, Inc., part of the company)
    • 7.4.9.1. Participant's Overview
    • 7.4.9.2. Financial Performance
    • 7.4.9.3. Product Benchmarking
    • 7.4.9.4. Recent Developments/ Strategic Initiatives
  • 7.4.10. Elekta AB
    • 7.4.10.1. Participant's Overview
    • 7.4.10.2. Financial Performance
    • 7.4.10.3. Product Benchmarking
    • 7.4.10.4. Recent Developments/ Strategic Initiatives

List of Tables

• Table 1 List of abbreviation
• Table 2 U.S. Pancreatic Cancer Treatment Market, by country, 2018 - 2030 (USD Million)
• Table 3 U.S. Pancreatic Cancer Treatment Market, by Type, 2018 - 2030 (USD Million)
• Table 4 U.S. Pancreatic Cancer Treatment Market, by Treatment, 2018 - 2030 (USD Million)
• Table 5 U.S. Pancreatic Cancer Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information Procurement
• Fig. 3 Primary Research Pattern
• Fig. 4 Market Research Approaches
• Fig. 5 Value Chain-Based Sizing & Forecasting
• Fig. 6 Market Formulation & Validation
• Fig. 7 U.S. Pancreatic Cancer Treatment Market Segmentation
• Fig. 8 Market Snapshot, 2024
• Fig. 9 Market Trends & Outlook
• Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
• Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 14 Porter's Five Forces Analysis
• Fig. 15 U.S. Pancreatic Cancer Treatment Market: Type movement analysis
• Fig. 16 U.S. Pancreatic Cancer Treatment Market: Type outlook and key takeaways
• Fig. 17 U.S. Exocrine pancreatic cancer treatment market estimates and forecasts, 2018 - 2030
• Fig. 18 U.S. Endocrine pancreatic cancer treatment market estimates and forecasts, 2018 - 2030
• Fig. 19 U.S. Pancreatic cancer treatment market: Treatment movement analysis
• Fig. 20 U.S. Pancreatic cancer treatment market: Treatment outlook and key takeaways
• Fig. 21 U.S. Chemotherapy market estimates and forecasts, 2018 - 2030
• Fig. 22 U.S. Radiation Therapy market estimates and forecasts, 2018 - 2030
• Fig. 23 U.S. Others market estimates and forecasts, 2018 - 2030
• Fig. 24 U.S. Pancreatic cancer treatment market: Distribution Channel movement analysis
• Fig. 25 U.S. Pancreatic cancer treatment market: Distribution Channel outlook and key takeaways
• Fig. 26 U.S. Hospital Pharmacies market estimates and forecasts, 2018 - 2030
• Fig. 27 U.S. Retail Pharmacies market estimates and forecasts, 2018 - 2030
• Fig. 28 U.S. Others market estimates and forecasts, 2018 - 2030